我們已在上線！進一步了解

Orthofix Medical

OFIX

市值 US$3.82億

9.38 USD

-0.21

2.19%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

9.38

0.00

0%

1天

-2.19%

5天

2.51%

1個月

5.39%

3個月

-21.11%

6個月

-24.29%

今年迄今

-36.79%

1年

-38.49%

5年

-74.07%

10年

-76.47%

關於： Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.

員工： 1,605

醫療保健醫療器材

新聞

正面

中性

負面

市場情緒 3個月

正面 30.8%

中性 61.5%

負面 7.7%

Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Orthofix Medical Inc. (NASDAQ: OFIX) concerning possible breaches of fiduciary duties. If you are a current shareholder of OFIX, you can request additional information here: https://zlk.com/cases/orthofix-medical-inc-class-action-lawsuit-ofix-2 or contact Joseph E.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Orthofix Medical Inc. (NASDAQ: OFIX)

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook

Orthofix Medical NASDAQ: OFIX executives said the company's updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook

Orthofix Medical Q2 Earnings Call Highlights

Orthofix Medical NASDAQ: OFIX reported second-quarter results that management said reflected improving operating trends across several businesses, while continued weakness among smaller U.S. spine distributors remained a headwind. The company reiterated its focus on commercial productivity, disciplined investment and profitable growth rather than pursuing revenue growth at any cost.

Orthofix Medical Q2 Earnings Call Highlights

Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript

Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript

Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Bet on 5 Top-Ranked Stocks With Rising P/E

Zacks Investment Research

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates

Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.13 per share a year ago.

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates

Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, reflecting progress toward a more focused and consistent operating model. The Company also raised its full-year 2026 guidance for both net sales and adjusted EBITDA. All pro forma measures contained within this release exclude the impact of the discontinued M6™ product lines. Highlights Second quart.

Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress

Zacks Investment Research

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for

Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?

查看新聞排名

價格圖表採用Lightweight Charts™實作